Retisert is a drug owned by Bausch And Lomb Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 22, 2019. Details of Retisert's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6217895 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) |
Expired
|
| US6548078 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
Mar, 2019
(5 years ago) |
Expired
|
FDA has granted several exclusivities to Retisert. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Retisert, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Retisert.
Exclusivity Information
Retisert holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Retisert's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Apr 08, 2012 |
US patents provide insights into the exclusivity only within the United States, but Retisert is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Retisert's family patents as well as insights into ongoing legal events on those patents.
Retisert's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Retisert's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 22, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Retisert Generic API suppliers:
Fluocinolone Acetonide is the generic name for the brand Retisert. 27 different companies have already filed for the generic of Retisert, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Retisert's generic
Alternative Brands for Retisert
Retisert which is used for managing chronic non-infectious uveitis affecting the posterior segment of the eye., has several other brand drugs in the same treatment category and using the same active ingredient (Fluocinolone Acetonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alimera Sciences Inc |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Fluocinolone Acetonide. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Alimera Sciences Inc |
| |
| Galderma Labs Lp |
| |
| Laboratorios Salvat |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluocinolone Acetonide, Retisert's active ingredient. Check the complete list of approved generic manufacturers for Retisert
About Retisert
Retisert is a drug owned by Bausch And Lomb Inc. It is used for managing chronic non-infectious uveitis affecting the posterior segment of the eye. Retisert uses Fluocinolone Acetonide as an active ingredient. Retisert was launched by Bausch And Lomb in 2005.
Approval Date:
Retisert was approved by FDA for market use on 08 April, 2005.
Active Ingredient:
Retisert uses Fluocinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Fluocinolone Acetonide ingredient
Treatment:
Retisert is used for managing chronic non-infectious uveitis affecting the posterior segment of the eye.
Dosage:
Retisert is available in implant form for intravitreal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.59MG | IMPLANT | Prescription | INTRAVITREAL |